Adaptive Biotechnologies Announces New Data Demonstrating the Benefit of Serial MRD Testing with the clonoSEQ® Assay in Patients with Blood Cancers at the 63rd ASH Annual Meeting
December 13, 2021 16:05 ET
|
Adaptive Biotechnologies
Analysis of the MASTER trial (Abstract 481) showed clonoSEQ’s ability to measure deep and durable responses and permit treatment discontinuation in multiple myeloma patientsData in more than 30...
Neoleukin Therapeutics Announces Preclinical Data Highlighting Activity of NL-201 in Hematologic Malignancies at 63rd American Society of Hematology Annual Meeting (ASH 2021)
December 11, 2021 17:30 ET
|
Neoleukin Therapeutics, Inc.
– Poster presentation highlights NL-201 activity in multiple myeloma stem cell transplant model – – Abstract reports activity of NL-201 as monotherapy and anti-PD1 combination in non-Hodgkin lymphoma...
Proteona announces multiple ASH presentations highlighting novel gene signatures in hematological cancers identified using advanced single-cell biomarker discovery platform
December 08, 2021 06:38 ET
|
Proteona
SINGAPORE, Dec. 08, 2021 (GLOBE NEWSWIRE) -- Proteona, a single-cell precision medicine company, today announced that three abstracts from the company and its collaborators have been accepted for...
Aronora Announces Clinical Data to Be Presented at the 63rd American Society of Hematology Annual Meeting
December 06, 2021 08:00 ET
|
Aronora, Inc
PORTLAND, Ore., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Aronora Inc., a clinical-stage biotechnology company developing innovative therapies for hematologic diseases, today announced that clinical data...
Adaptive Biotechnologies Receives Updated Medicare Coverage for its Minimal Residual Disease (MRD) Assay, clonoSEQ® for Blood Cancer Patients
November 11, 2021 17:52 ET
|
Adaptive Biotechnologies
Local coverage determination (LCD) confirms access to the only FDA-cleared in vitro diagnostic to detect and monitor minimal residual disease (MRD) from bone marrow and blood sample types in certain...
Aptose Clinical Data to be Presented at the 2021 ASH Annual Meeting
November 04, 2021 09:00 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting...
Plasma Fractionation Market Size ($40,731.98Mn by 2028) Lead by Immunoglobulin (6.3% CAGR) Impact of Coronavirus Outbreak and Global Analysis & Forecast by TheInsightPartners.com
November 02, 2021 14:43 ET
|
The Insight Partners
New York, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Plasma Fractionation Market: Key InsightsAccording to our latest study on Plasma Fractionation Market Size, Share, Revenue, Forecast to 2028 - COVID-19...
Point-of-Care Molecular Diagnostics Market Size ($5,381.18Mn by 2028) Lead by Assays and Kits (13.4% CAGR) Impact of Coronavirus Outbreak and Global Analysis & Forecast by TheInsightPartners.com
October 29, 2021 13:28 ET
|
The Insight Partners
New York, Oct. 29, 2021 (GLOBE NEWSWIRE) -- Point-of-Care Molecular Diagnostics Market: Key InsightsAccording to our new research study on Point-of-Care Molecular Diagnostics Market Size and...
Plasma Fractionation Market Worth $41.4 Billion by 2027 - Market Size, Share, Forecasts, & Trends Analysis Report with COVID-19 Impact by Meticulous Research®
October 21, 2021 12:30 ET
|
Meticulous Market Research Pvt. Ltd.
Redding, California, Oct. 21, 2021 (GLOBE NEWSWIRE) -- According to a new market research report “Plasma Fractionation Market by Product [Immunoglobulins (Intravenous, Subcutaneous),...
Provectus Biopharmaceuticals Provides Update on Research into Oral Administration of PV-10® Immunotherapy for Treatments of Hematology, Oncology, and Virology
October 04, 2021 09:00 ET
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today provided an update on the Company’s research into the systemic administration of Provectus’ investigational...